Portal de investigación
A MULTICENTER, RANDOMIZED, PLACEBO AND ACTIVE COMPARATOR-CONTROLLED CLINICAL TRIAL TO STUDY THE EFFICACY, SAFETY AND PHARMACOKINETICS OF TILDRAKIZUMAB IN PEDIATRIC SUBJECTS FROM 6 TO <18 YEARS OF AGE WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS.
Datos básicos
- Protocolo:
- TILD-19-02
- EUDRACT:
- 2019-003551-11
- NCT:
- Centro:
- HOSPITAL DE MANISES
- Año de incio:
- 2020
- Año de finalización:
- 2020
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
SUN PHARMACEUTICALS GLOBAL FZE
Resultados del Ensayo Clínico
[Translated article] Risk of a Second Skin Cancer in a Cohort of Patients With Nonmelanoma Skin Cancer - Basal Cell Carcinoma or Squamous Cell Carcinoma - Treated With Mohs Micrographic Surgery: A National Prospective Cohort Study.
Minano Medrano, R.; (...); Garcia-Doval, I
Article. 10.1016/j.ad.2022.01.035. 2022
Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting
Daudén E; (...); Llamas-Velasco M
Article. 10.1111/ijd.16915. 2024
Epigenetic characterization of the inflammatory hidradenitis suppurativa phenotype
Martorell, Antonio; (...); Sandoval, Juan
Meeting Abstract. 2023
Risk of a Second Skin Cancer in a Cohort of Patients With Nonmelanoma Skin Cancer -Basal Cell Carcinoma or Squamous Cell Carcinoma-Treated With Mohs Micrographic Surgery: A National Prospective Cohort Study.
Miñano Medrano R; (...); García-Doval I
Article. 10.1016/j.ad.2022.01.003. 2022
Safety and Efficacy Profile of Bimekizumab in Patients With Psoriasis and Psoriatic Arthritis: An 18-Patient Case Series.
Melgosa Ramos, F J; (...); Martorell, A
Article. 10.1016/j.ad.2024.08.009. 2024